drugset / Trial / NCT05298020
Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, exploratory study to evaluate efficacy and safety of envafolimab combined with endostar and nab-paclitaxel plus gemcitabine for first-line treatment of advanced pancreatic cancer.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2022-12-01
- Completion
- 2023-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Endostar | Protein / enzyme biologic | 210 mg | Intravenous |
| Subject | Envafolimab | Monoclonal antibody | 400 mg | Subcutaneous |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |